Test Report Status

<u>Final</u>





Biological Reference Interval Units

PATIENT NAME : ANITA DHYANI	REF. DOCTOR :	: SELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		

Results

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP AB	OVE 40FEMALE			
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	13.0	12.0 - 15.0	g/dL	
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	4.47	3.8 - 4.8	mil/µL	
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	11.70 High	4.0 - 10.0	thou/µL	
PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY	303	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	38.7	36.0 - 46.0	%	
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	86.7	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	29.1	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	33.5	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	13.3	11.6 - 14.0	%	
MENTZER INDEX	19.4			
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	9.6	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	48	40 - 80	%	
LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	31	20 - 40	%	
MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	7	2.0 - 10.0	%	
EOSINOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	13 High	1.0 - 6.0	%	



Dr. Reena Mittal, MD Senior Consultant Hematopathologist



Dr. Sushant Chikane Consultant Pathologist



View Report







REF. DOCTOR : SELF PATIENT NAME : ANITA DHYANI CODE/NAME & ADDRESS : C000138379 Female ACCESSION NO : 0065WC002146 AGE/SEX :51 Years ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ANITF07017265 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 20/03/2023 08:41:50 DELHI REPORTED :21/03/2023 15:39:47 NEW DELHI 110030 ABHA NO : 8800465156 **Test Report Status** Results Biological Reference Interval **Final** Units

<u>Indi</u>			
BASOPHILS	1	0 - 1	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	5.62	2.0 - 7.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	3.60 High	1.0 - 3.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.82	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	1.52 High	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0.12 High	0.02 - 0.10	thou/µL
METHOD : CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.6		
METHOD : CALCULATED			
MORPHOLOGY			
RBC	PREDOMINANTLY NORM	OCYTIC NORMOCHROMIC	
METHOD : MICROSCOPIC EXAMINATION			
WBC	EOSINOPHILIA PRESEN	Γ	
METHOD : MICROSCOPIC EXAMINATION			
PLATELETS	ADEQUATE		
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY			

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist



Dr. Sushant Chikane Consultant Pathologist





View Report

Page 2 Of 20

View Details







REF. DOCTOR : SELF PATIENT NAME : ANITA DHYANI CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WC002146 AGE/SEX :51 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ANITF07017265 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 20/03/2023 08:41:50 DELHI REPORTED :21/03/2023 15:39:47 **NEW DELHI 110030** ABHA NO : 8800465156

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

Biological Reference Interval Units

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HE	ALTH CHECKUP ABOVE 40FEMALE		
ERYTHROCYTE SEDIMENTAT BLOOD	TON RATE (ESR),WHOLE		
E.S.R	15	0 - 20	mm at 1 hr
METHOD : AUTOMATED (PHOTOMETRIC)	AL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)		

Interpretation(s) ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

Dr. Sushant Chikane Consultant Pathologist





View Repor

Page 3 Of 20







PATIENT NAME : ANITA DHYANI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WC002146 AGE/SEX :51 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ANITF07017265 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 20/03/2023 08:41:50 DELHI REPORTED :21/03/2023 15:39:47 NEW DELHI 110030 ABHA NO : 8800465156

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP 0 METHOD : HAEMAGGLUTINATION (AUTOMATED) POSITIVE RH TYPE METHOD : HAEMAGGLUTINATION (AUTOMATED)

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane **Consultant Pathologist**



Page 4 Of 20







PATIENT NAME : ANITA DHYANI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female
	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	i	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		
	1	

Test Report	Status	<u>Final</u>
-------------	--------	--------------

Results

Biological Reference Interval Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	ABOVE 40FEMALE		
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT BLOOD	A WHOLE		
HBA1C	5.8 High	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	% 6.5
METHOD : ION- EXCHANGE HPLC		(
ESTIMATED AVERAGE GLUCOSE(EAG) GLUCOSE FASTING,FLUORIDE PLASMA	119.8 High	< 116	mg/dL
FBS (FASTING BLOOD SUGAR)	99	Normal <100 Impaired fasting glucose:10 125 Diabetes mellitus: > = 126 more than 1 occassion) (ADA guidelines 2021)	
METHOD : SPECTROPHOTOMETRY HEXOKINASE		()	
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR)	79	Normal <140 Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occassion) ADA guideline 2021	mg/dL
METHOD : SPECTROPHOTOMETRY HEXOKINASE			
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	205 High	Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC	- CHOLETSEROL OXIDASE, ESTER	ASE, PEROXIDASE	
TRIGLYCERIDES	130	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH	I GLYCEROL BLANK		

D : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 5 Of 20









PATIENT NAME : ANITA DHYANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WC002146	AGE/SEX : 51 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		

Test Report Status	<u>Final</u>	Re	esults	Biological Reference Interva	al Units
	ETRY, HOMOGENEOUS DIRECT ENZYMAT	40		At Risk: < 40 Desirable: > or = 60	mg/dL
CHOLESTEROL LDL			High	Optimal : < 100 Near optimal/above optimal 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL :
METHOD : CALCULATED PAR	ROL	165	High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	
VERY LOW DENSITY		26.0	0	< or = 30.0	mg/dL
METHOD : CALCULATED PAR	AMETER	5.1	High	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
METHOD : CALCULATED PAR	AMETER				
LDL/HDL RATIO	AMETER	3.5	High	Desirable/Low Risk : 0.5 - 3 Borderline/Moderate Risk : - 6.0 High Risk : > 6.0	
Interpretation(s)					
LIVER FUNCTION PR	OFILE, SERUM				
BILIRUBIN, TOTAL METHOD : SPECTROPHOTOM	ETRY, COLORIMETRIC -DIAZO METHOD	0.22	2	Upto 1.2	mg/dL
BILIRUBIN, DIRECT METHOD : SPECTROPHOTOM	ETRY, JENDRASSIK & GROFF - DIAZOTIZ	0.13	3	< or = 0.3	mg/dL
BILIRUBIN, INDIREC METHOD : CALCULATED PAR		0.09	9	0.0 - 0.9	mg/dL
TOTAL PROTEIN		6.6		6.0 - 8.0	g/dL

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist











PATIENT NAME : ANITA DHYANI		REF. DOCTOR : SELF	2
CODE/NAME & ADDRESS :C000138379 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 00 PATIENT ID : AN CLIENT PATIENT ID: ABHA NO :	ITF07017265 DR RE	E/SEX :51 Years Female AWN : CEIVED :20/03/2023 08:41:50 PORTED :21/03/2023 15:39:47
Test Report Status <u>Final</u>	Results	Biological Ref	ference Interval Units
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REA	GENT BLANK, SERUM BLANK		
ALBUMIN	4.3	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG)		5.57 7.54	3, 32
GLOBULIN	2.3	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER	2.5	210 515	5,
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.9	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPH		Upto 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPH	29	Upto 33	U/L
ALKALINE PHOSPHATASE	77	35 - 104	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC		-	
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC -	13 G-GLUTAMYL-CARBOXY-NITRO	< 40 ANILIDE - IFCC	U/L
LACTATE DEHYDROGENASE METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-II	210 =cc	< 223	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC	7	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE	0.52 Low	0.60 - 1.10	mg/dL

13.50

4.1

6.6

4.3

8 - 15

2.4 - 5.7

6.0 - 8.0

3.97 - 4.94

8. wadal R

BUN/CREAT RATIO

URIC ACID, SERUM

TOTAL PROTEIN

ALBUMIN, SERUM

URIC ACID

ALBUMIN

METHOD : CALCULATED PARAMETER

TOTAL PROTEIN, SERUM

METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE

METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK

METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist

Page 7 Of 20



mg/dL

g/dL

g/dL







PATIENT NAME : ANITA DHYANI	REF. DOC	CTOR : SELF
CODE/NAME & ADDRESS :C000138379	ACCESSION NO : 0065WC00214	46 AGE/SEX : 51 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		
Test Report Status <u>Final</u>	Results Bio	ological Reference Interval Units

GLOBULIN			
GLOBULIN	2.3	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	141	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	4.80	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	105	98 - 106	mmol/L
METHOD : ISE INDIRECT			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s) GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist

Page 8 Of 20



Details







REF. DOCTOR : SELF PATIENT NAME : ANITA DHYANI CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WC002146 AGE/SEX :51 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ANITF07017265 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 20/03/2023 08:41:50 DELHI REPORTED :21/03/2023 15:39:47 **NEW DELHI 110030** ABHA NO 8800465156 Test Report Status Results **Biological Reference Interval Final** Units

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

 a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE FASTING, FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency

diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give vellow discoloration in jaundice

Elevated levels results from increased bilirubin production (eq, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eq, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels



Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 9 Of 20

View Report

iew Details







REF. DOCTOR : SELF PATIENT NAME : ANITA DHYANI CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WC002146 AGE/SEX :51 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ANITF07017265 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 20/03/2023 08:41:50 DELHI REPORTED :21/03/2023 15:39:47 NEW DELHI 110030 ABHA NO : 8800465156

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

(hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:


• Myasthenia Gravis, Muscuophy URIC ACID, SERUM-**Causes of Increased levels:**-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 10 Of 20





View Repor







PATIENT NAME : ANITA DHYANI	REF. DOCTOR : S	SELF
	ACCESSION NO : 0065WC002146 PATIENT ID : ANITE07017265	AGE/SEX :51 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :21/03/2023 15:39:47

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

CLINICAL PATH - URINALYSIS			
MEDI WHEEL FULL BODY HEALTH CHECKUP AB	OVE 40FEMALE		
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION, URINE			
PH	6.0	5.00 - 7.50	
SPECIFIC GRAVITY	1.010	1.010 - 1.030	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NOT DETECTED		
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	0-1	0-5	/HPF
EPITHELIAL CELLS	2-3	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	
METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTER	GRATED AUTOMATED SYSTEM		

Interpretation(s)

g.g.wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist













PATIENT NAME : ANITA DHYANI	REF. DOCTOR : S	SELF
	ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female
	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		
	i	

Test Report Status Final Results

Biological Reference Interval Units

	CYTOLOGY
MEDI WHEEL FULL BODY HEALTH CHECKUP AB	OVE 40FEMALE
PAPANICOLAOU SMEAR	
TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED (2CW- 7518)
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.
MICROSCOPY	THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW INTERMEDIATE SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, FEW CLUSTERS OF ENDOCERVICAL CELLS IN THE MODERATE BACKGROUND OF POLYMORPHS.
INTERPRETATION / RESULT	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY
-	REACTIVE CELLULAR CHANGES ASSOCIATED WITH INFLAMMATION (INCLUDES TYPICAL REPAIR - MODERATE INFLAMMATION)
ENDOMETRIAL CELLS (IN A WOMAN >/= 45 YRS)	ABSENT

Comments

Suggestions / Guidelines: (REF: THE BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY, 2014, 3rd Edition) ADVISED REPEAT SMEAR, AFTER TREATMENT OF INFLAMMATION.

1) Please note papanicolaou smear study is a screening procedure for cervical cancer with inherent false negative results, hence should be interpreted with caution.

2) No cytologic evidence of hpv infection in the smears studied.

3) Primary screening of papanicolaou smears is carried out by cytotechnologist with 100% rescreening and reporting by surgical pathologist.



Dr.Priyanka Kembhavi (Reg.No.2014/05/2240) Histopathologist



Page 12 Of 20

Details







PATIENT NAME : ANITA DHYANI	REF. DOCTOR : SELF		
	ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female	
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : ANITF07017265	DRAWN :	
DELHI		RECEIVED : 20/03/2023 08:41:50	
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47	
8800465156			

Test Report Status Final

Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

MICROSCOPIC EXAMINATION, STOOL

REMARK

Interpretation(s)

TEST CANCELLED AS SPECIMEN NOT RECEIVED



Dr. Ekta Patil Microbiologist

PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : 022 - 67801212 CIN - U74899PB1995PLC045956 Page 13 Of 20





View Repor







PATIENT NAME : ANITA DHYANI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female
	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		

Test Report Status	<u>Final</u>
--------------------	--------------

Results

Biological Reference Interval Units

SPEC	CIALISED CHEMISTRY - HO	RMONE	
MEDI WHEEL FULL BODY HEALTH CHECK	UP ABOVE 40FEMALE		
THYROID PANEL, SERUM			
Τ3	157.0	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	D
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE II			
Τ4	9.24	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70)
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE I	MMUNOASSAY		
TSH (ULTRASENSITIVE)	2.310	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL
METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMM	IUNOASSAY		

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. owidctlparowidctlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

			24		
Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions

8. wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 14 Of 20

View Repor







REF. DOCTOR : SELF		
ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female	
PATIENT ID : ANITE07017265	DRAWN :	
CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50	
ABHA NO :	REPORTED :21/03/2023 15:39:47	
	ACCESSION NO : 0065WC002146 PATIENT ID : ANITF07017265 CLIENT PATIENT ID:	

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
		2.0			Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	 (1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist







Vie<u>w Report</u>

Page 15 Of 20





PATIENT NAME : ANITA DHYANI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138379 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0065WC00214 PATIENT ID : ANITF07017265 CLIENT PATIENT ID : ABHA NO :	6 AGE/SEX :51 Years Female DRAWN : RECEIVED :20/03/2023 08:41:50 REPORTED :21/03/2023 15:39:47	
Test Report Status <u>Final</u>	Results Biol	ogical Reference Interval Units	
MEDI WHEEL FULL BODY HEALTH CHECKUP A XRAY-CHEST	BOVE 40FEMALE		
IMPRESSION	NO ABNORMALITY DETECTED		
TMT OR ECHO			
TMT OR ECHO	2D ECHO DONE NORMAL		
ECG			
ECG	DONE		
MAMOGRAPHY (BOTH BREASTS)			
MAMOGRAPHY BOTH BREASTS	FINDINGS ARE SUGGESTIVE OF FIBROADENOMA IN LEFT BREAS BIRADS II		
MEDICAL HISTORY			
RELEVANT PRESENT HISTORY	MIGRAINE - MANY MONTHS. HISTORY OF ANXIETY - 2019. CVS 2ND DOSE.		
RELEVANT PAST HISTORY	NOT SIGNIFICANT		
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT		
MENSTRUAL HISTORY (FOR FEMALES)	MENOPAUSAL.		
RELEVANT FAMILY HISTORY	HYPERTENSION. HEART DISEASE. DIABETES.		
HISTORY OF MEDICATIONS	NOT SIGNIFICANT		
ANTHROPOMETRIC DATA & BMI			
HEIGHT IN METERS	1.52	mts	
WEIGHT IN KGS.	57	Kgs	
BMI		& Weight Status as followg/sqmts w 18.5: Underweight	

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL	HEALTHY
BUILT / SKELETAL FRAMEWORK	AVERAGE

Dr.Rajesh Nayak Consultant Radiologist

Page 16 Of 20



View Details

18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese





PATIENT NAME : ANITA DHYANI REF. DOCTOR : SELF CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WC002146 AGE/SEX :51 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ANITF07017265 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 20/03/2023 08:41:50 DELHI REPORTED :21/03/2023 15:39:47 NEW DELHI 110030 ABHA NO : 8800465156

Test Report Status <u>Final</u>

Results

Biological Reference Interval Units

FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER	
THYROID GLAND	NOT ENLARGED	
CAROTID PULSATION	NORMAL	
TEMPERATURE	NORMAL	
PULSE	80/MIN, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT	
RESPIRATORY RATE	NORMAL	
CARDIOVASCULAR SYSTEM		
BP	118/82 MM HG	mm/Hg
	(SUPINE)	
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
PER ABDOMEN		
APPEARANCE	NORMAL	
VENOUS PROMINENCE	ABSENT	
LIVER	NOT PALPABLE	
SPLEEN	NOT PALPABLE	
HERNIA	ABSENT	
CENTRAL NERVOUS SYSTEM		
HIGHER FUNCTIONS	NORMAL	

Dr.Rajesh Nayak Consultant Radiologist

PERFORMED AT : SRL Ltd PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA Tel : 09152729959/9111591115, Fax : CIN - U74899PB1995PLC045956





View Details View Report





PATIENT NAME : ANITA DHYANI	REF. DOCTO	K: SELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units
CRANIAL NERVES	NORMAL	
CEREBELLAR FUNCTIONS	NORMAL	
SENSORY SYSTEM	NORMAL	
MOTOR SYSTEM	NORMAL	
REFLEXES	NORMAL	
MUSCULOSKELETAL SYSTEM		
SPINE	NORMAL	
JOINTS	NORMAL	
BASIC EYE EXAMINATION		
CONJUNCTIVA	NORMAL	
EYELIDS	NORMAL	
EYE MOVEMENTS	NORMAL	
CORNEA	NORMAL	
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (6/6)	
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (6/6)	
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (N/6)	
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (N/6)	
COLOUR VISION	OUT OF 17 NUMBERED PLATES 17	
BASIC ENT EXAMINATION		
EXTERNAL EAR CANAL	NORMAL	
TYMPANIC MEMBRANE	NORMAL	
NOSE	NO ABNORMALITY DETECTED	
SINUSES	TENDERNESS	
THROAT	NO ABNORMALITY DETECTED	
TONSILS	NOT ENLARGED	
SUMMARY		
RELEVANT HISTORY	MIGRAINE - MANY MONTHS. HISTORY OF ANXIETY - 2019. CVS 2ND DOSE.	
	NEAR VISION BOTH EYES WITHOUT	

Dr.Rajesh Nayak Consultant Radiologist

PERFORMED AT : SRL Ltd PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA Tel : 09152729959/9111591115, Fax : CIN - U74899PB1995PLC045956

Page 18 Of 20







PATIENT NAME : ANITA DHYANI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138379 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	ACCESSION NO : 0065WC002146 PATIENT ID : ANITF07017265	AGE/SEX : 51 Years Female DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED :20/03/2023 08:41:50 REPORTED :21/03/2023 15:39:47
8800465156	Desulto Biological	Deference Interval Units
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

RELEVANT LAB INVESTIGATIONS	RAISED EOSINOPHILS (13) RAISD WBC (11.70) LOW CREATININE (0.52) RAISED TOTAL CHOLESTEROL (205) RAISED NON HDL CHOLESTEROL (165) RAISED LDL CHOLESTEROL (139) RAISED HBA1C (5.8)
RELEVANT NON PATHOLOGY DIAGNOSTICS	RAISED EAG (119.8) SONO - MILD FATTY LIVER
RELEVANT NON PATHOLOGY DIAGNOSTICS	ECG (VPC)
REMARKS / RECOMMENDATIONS	AVOID OUTSIDE FOOD IN DIET REDUCE FATTY AND PROCESSED FOOD IN DIET REDUCE SUGARS, SWEETS IN DIET

Dr.Rajesh Nayak Consultant Radiologist

PERFORMED AT :

SRL Ltd PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA Tel : 09152729959/9111591115, Fax : CIN - U74899PB1995PLC045956

Page 19 Of 20









PATIENT NAME : ANITA DHYANI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WC002146	AGE/SEX :51 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : ANITF07017265	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 20/03/2023 08:41:50
NEW DELHI 110030	ABHA NO :	REPORTED :21/03/2023 15:39:47
8800465156		
	1	1
Test Report Status Final	Results Biological	Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

<u>Final</u>

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

MILD FATTY LIVER.

Interpretation(s)

MEDIĊAL

HISTORY-*** THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form. 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services. 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment

breakdown / natural calamities / technical downtime or any other unforeseen event. 4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care
- (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr.Rajesh Nayak Consultant Radiologist

PERFORMED AT :

SRL Ltd PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST) MUMBAI, 400093 MAHARASHTRA, INDIA Tel : 09152729959/9111591115, Fax : CIN - U74899PB1995PLC045956





